turnstonebio.com (TSBX) Long-Term Debt to Capital Ratio

Turnstone Biologics (TSBX) focuses on developing personalized cancer treatments using lymphocytes, relying on future reimbursements from insurance companies and government agencies. The current stage of clinical trials generates no revenue, while the expansion of the product portfolio increases biotech infrastructure costs. Meanwhile, financial stability is maintained by investor capital and a lack of debt, as confirmed by the market price of 0.00 shown on this chart.

Turnstone Biologics is developing innovative TIL vaccines to combat solid tumors. This long-term debt-to-equity ratio reflects the volume of borrowings exceeding one year relative to equity, adjusted for inflation. The metric assesses the real cost of servicing obligations and the risk of default. Low leverage in immuno-oncology minimizes risks but may constrain expansion into a massive market. The asset maintains a stable financial structure.